Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product…
August 5, 2026
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
CRANBURY, N.J. and SUZHOU,China, Aug. 5, 2026 /PRNewswire/ — Recently, Porton Advanced…
August 5, 2026
Cheche Group Regains Compliance with Nasdaq Minimum Bid Price Requirement
BEIJING, Aug. 5, 2026 /PRNewswire/ — Cheche Group Inc. (NASDAQ: CCG) ("Cheche"…